Navigation Links
Vaccinex Antibody Licensed to GlaxoSmithKline
Date:2/15/2008

ROCHESTER, N.Y., Feb. 15 /PRNewswire/ -- EUSA Pharma (Oxford, UK), a Vaccinex collaboration partner, has announced that it has licensed OP-R003, a human anti-interleukin-6 antibody discovered by Vaccinex, to GlaxoSmithKline.

According to the terms of the product license, GSK will pay an up-front license fee, development milestones, and royalties on product sales to acquire the exclusive world-wide rights to develop and commercialize OP-R003 for the treatment of rheumatoid arthritis and other disease indications. Vaccinex will share 50% of fees, payments and royalties. The antibody was discovered by Vaccinex utilizing its ActivMAb(R) antibody discovery technology and first licensed for co-development by EUSA Pharma (formerly OPi SA).

"We are pleased that our collaboration in the discovery and co-development of OP-R003 has attracted such a world-class partner as GSK. Together with previously announced antibody partnerships with Biocon, Ltd. and Teva Pharmaceutical, this transaction further validates the quality of human antibodies selected with Vaccinex's ActivMAb(R) antibody discovery technology," remarked Dr. Maurice Zauderer, Vaccinex's President and CEO.

Commenting on the acquisition, Brian McVeigh, GSK's Worldwide Business Development Director of M&A Strategy and Transactions, said, "Interleukin-6 is increasingly recognized as an important biological target in a range of diseases, and consequently OP-R003 has great potential to meet a number of unmet medical needs."

About Vaccinex

Vaccinex, Inc. is a biotechnology company engaged in the discovery and development of human monoclonal antibodies and other biologics to treat a variety of serious illnesses, including autoimmune disease, inflammation, multiple sclerosis, and cancer. The company's patented ActivMAb(R) technology allows for the direct selection of high affinity, fully human monoclonal antibodies that would be difficult or impossible to identify using other systems. Vaccinex, on its own or with its partners, has advanced several antibodies from discovery and lead validation into IND-directed pre-clinical drug development. The company is headquartered in Rochester, NY, USA. For more information, please visit http://www.vaccinex.com.

Press Contact

Raymond E. Watkins, Vice President of Operations & Officer

Vaccinex, Inc.

+1.585.271.2700 Ext. 105

E-mail: rwatkins@vaccinex.com


'/>"/>
SOURCE Vaccinex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vaccinex, Inc. Announces Award of Key Patent in Europe for its Antibody Discovery Technology (ActivMab(R))
2. ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells
3. Human Genome Sciences and Xencor Announce Antibody Collaboration
4. Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
5. ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody
6. Roche Files IND for Second Genmab Antibody
7. Genmab A/S - R1507 Antibody to Enter Phase II Study to Treat Sarcoma
8. Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic
9. ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody
10. Antibody Engineering Company f-star Raises EUR 3.0 Million in a Second Closing of its Series A Financing Round From Novo A/S
11. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... March 23, 2017  BioPharmX Corporation (NYSE MKT: ... the dermatology market, today reported financial results for ... and will provide an update on the company,s ... "We are pleased to report that ... BioPharmX," said President Anja Krammer. "We achieved key ...
(Date:3/23/2017)... , March 23, 2017  Agriculture technology company ... A financing and note conversion to commercialize its Cool ... is focused on developing products that are simultaneously profitable ... million in the last 18 months. This latest round ... Bridge Venture Partners. The company,s primary ...
(Date:3/22/2017)... 22, 2017  Ascendis Pharma A/S (Nasdaq: ASND), ... technology to address significant unmet medical needs in ... full year ended December 31, 2016. ... company as we broadened our pipeline and pursued ... disease company with an initial focus on endocrinology," ...
(Date:3/22/2017)... March 22, 2017 The global ... a research report by Transparency Market Research (TMR). The ... Inc., and AbbVie Inc., accounted for a share of ... players in this market are focusing aggressively on mergers, ... which is likely to lead to market consolidation in ...
Breaking Biology Technology:
(Date:2/24/2017)... Spain , Feb. 24, 2017  EyeLock LLC, a ... demonstrate its elite iris biometric solution on the ... X16 LTE at Mobile World Congress 2017 ... Qualcomm,s Booth in Hall 3, Stand 3E10. ... the Qualcomm Haven™ security platform—a combination of ...
(Date:2/16/2017)... FRANCISCO , Feb. 16, 2017  Genos, ... today announced that it has received Laboratory Accreditation ... CAP Accreditation is presented to laboratories that meet ... who demonstrate scientifically rigorous processes. "Genos ... excellence in laboratory practices. We,re honored to be ...
(Date:2/10/2017)... Feb 10, 2017 Research and ... "Personalized Medicine - Scientific and Commercial Aspects" to ... ... Diagnosis is integrated with therapy for selection of treatment as ... detection and prevention of disease in modern medicine. Biochip/microarray technologies ...
Breaking Biology News(10 mins):